Key facts
- Notable investors include HSG (Hong Kong), Duce Capital, Grower Venture Capital, NSR Financial, Shanghai Meihong Private Equity Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BETACURE
- ·The full record, as it builds
Funding rounds
No funding rounds for BETACURE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BETACURE
Operator of a biotechnology firm intended to advance stem cell culture, differentiation, and industrial-scale applications.The company offers proprietary in vitro preparation and encapsulation of stem cell-derived pancreatic islet cells, enabling biomedical researchers and healthcare innovators to pursue cutting-edge regenerative therapies.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
BETACURE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BETACURE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BETACURE in its N-PORT filings yet. We sweep new filings monthly.